Division of Hematology Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA.
Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA.
Semin Nephrol. 2020 Jan;40(1):76-85. doi: 10.1016/j.semnephrol.2019.12.009.
Immune checkpoint inhibitors have quickly become a critical component to the management of advanced renal cell carcinoma. These therapies have been approved for patients who are treatment-naive and who have progressed on antiangiogenesis agents. Combinations of immune checkpoint inhibitors with antiangiogenesis agents show significant response rates and prolong survival. Adverse events associated with the use of checkpoint inhibition present unique challenges in the management of patients, and careful considerations are needed when checkpoint inhibitors are combined with antiangiogenesis agents. Nevertheless, the improvement in overall survival associated with these agents indicates that they will remain a vital component of kidney cancer treatment.
免疫检查点抑制剂已迅速成为晚期肾细胞癌治疗的重要组成部分。这些治疗方法已被批准用于治疗初治和抗血管生成药物进展的患者。免疫检查点抑制剂与抗血管生成药物联合使用显示出显著的反应率和延长的生存时间。使用检查点抑制相关的不良反应在患者管理方面带来了独特的挑战，当检查点抑制剂与抗血管生成药物联合使用时需要谨慎考虑。然而，这些药物带来的总体生存改善表明它们将仍然是肾癌治疗的重要组成部分。
